We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Psychiatry

Psychiatry

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Sexual Assault and the Long Shadow of the Body: Higher 5‑Year Risk of Functional Somatic Disorders and Chronic Widespread Pain
newscohort study

Sexual Assault and the Long Shadow of the Body: Higher 5‑Year Risk of Functional Somatic Disorders and Chronic Widespread Pain

By MedXY|Nov 14, 2025

A prospective Danish cohort found that adults reporting lifetime sexual assault had substantially higher 5‑year incidence of functional somatic disorders—especially multiorgan FSD and chronic widespread pain—after adjustment for psychosocia

Can Modafinil Break the Sleep–Mood Cycle in People Living with HIV?
HIV/AIDSHIVmodafinil

Can Modafinil Break the Sleep–Mood Cycle in People Living with HIV?

By MedXY|Nov 12, 2025

Sleep disorders and depression are common in people living with HIV. Modafinil may improve daytime sleepiness, fatigue and cognition—especially for OSA-related EDS or augmentation in depression—but HIV-specific RCT data and ART interaction

Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients
HIV/AIDSdepressionHIV

Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients

By MedXY|Nov 12, 2025

Sleep disturbances and mood disorders profoundly affect people living with HIV. Modafinil emerges as a promising therapy addressing daytime sleepiness, depression, and cognitive challenges, improving quality of life.

Not All Antidepressants Are the Same: Differential Cardiometabolic and Physiological Effects from a Large Network Meta‑analysis
Cardiologyantidepressantscardiometabolic risk

Not All Antidepressants Are the Same: Differential Cardiometabolic and Physiological Effects from a Large Network Meta‑analysis

By MedXY|Nov 10, 2025

A 151‑trial network meta‑analysis of 58,534 participants shows marked differences among 30 antidepressants in weight, blood pressure, heart rate, lipids, glucose and liver enzymes; findings support individualized choice and targeted baselin

High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening
GastroenterologyARFIDscreening

High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening

By MedXY|Nov 10, 2025

A 2023 population survey of 4,002 adults in the UK and US found that positive screens for avoidant/restrictive food intake disorder (ARFID) were common among people with disorders of gut–brain interaction (DGBI) and associated with greater

Gamma (40 Hz) Sensory Flicker Shows Promise for Insomnia but Needs Controlled Trials
Neurology40 Hzgamma entrainment

Gamma (40 Hz) Sensory Flicker Shows Promise for Insomnia but Needs Controlled Trials

By MedXY|Nov 9, 2025

A prospective observational study of 37 adults with insomnia reports high adherence and no serious adverse events with 40 Hz light–sound flicker and sleep-diary improvements in sleep onset, arousals, and total sleep time; limitations includ

How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target
Internal Medicineaerobic exercisechronic illness

How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target

By MedXY|Nov 8, 2025

A meta-analysis of 36 RCTs (n=2,500) found aerobic exercise significantly reduces depressive symptoms in people with chronic illness (Hedges’ g -0.73). A weekly dose of ≈405 MET‑min (≈120–135 min of moderate aerobic activity) reaches

Persistent Depressive Symptoms After MCI Strongly Predict Progression to Alzheimer’s Disease
NeurologyAlzheimer's diseasedepression

Persistent Depressive Symptoms After MCI Strongly Predict Progression to Alzheimer’s Disease

By MedXY|Nov 5, 2025

In an ADNI longitudinal cohort, persistently elevated depressive symptoms over 36 months after MCI diagnosis were associated with a dose‑dependent, substantially higher hazard of conversion to Alzheimer’s disease over long-term follow-up.

Depression, Anxiety and PTSD Associated With Earlier Onset of Alzheimer’s Disease: Psychiatric Burden Lowers Age at Symptom Onset
NeurologyAlzheimer's diseaseEarly-onset dementia

Depression, Anxiety and PTSD Associated With Earlier Onset of Alzheimer’s Disease: Psychiatric Burden Lowers Age at Symptom Onset

By MedXY|Nov 4, 2025

In two large Alzheimer cohorts, a history of depression, anxiety, or PTSD and an increased number of psychiatric comorbidities were associated with earlier age at AD symptom onset by up to ~7–8 years for multi-morbidity.

Circadian Dysregulation and Executive Dysfunction in Wolfram Syndrome: Toward Chrono‑Diagnosis and Chronotherapy
Neurologycircadian rhythms

Circadian Dysregulation and Executive Dysfunction in Wolfram Syndrome: Toward Chrono‑Diagnosis and Chronotherapy

By MedXY|Nov 4, 2025

Emerging evidence links WFS1-driven ER stress to serotonergic/cholinergic disruption, executive dysfunction, and circadian dysregulation in Wolfram syndrome. This article synthesizes recent data, outlines chrono‑informed clinical assessment

Recent Advances in Alcohol Metabolism: from the Gut to the Brain
Gastroenterologyalcohol metabolismbariatric surgery

Recent Advances in Alcohol Metabolism: from the Gut to the Brain

By MedXY|Nov 4, 2025

This article reviews the latest findings on human alcohol metabolism, covering evolutionary biology, systemic and brain-specific pathways, genetic and physiological modulators, clinical implications of metabolic variability, and emerging th

SPeCIFY: Practical Guidance for Inducing and Measuring Mental Fatigue in Movement Science
newsMental Fatigue

SPeCIFY: Practical Guidance for Inducing and Measuring Mental Fatigue in Movement Science

By MedXY|Nov 4, 2025

Clear, pragmatic recommendations to standardize how mental fatigue is induced, measured and reported in movement-science studies—centered on the SPeCIFY reporting checklist and multi-method assessment.

Group-Based Interventions to Reduce Gambling Involvement Among Male Football Fans
newsgroup-based therapypublic health

Group-Based Interventions to Reduce Gambling Involvement Among Male Football Fans

By MedXY|Nov 2, 2025

This case report summarizes the feasibility study of a group-based gambling prevention intervention among male football fans, revealing recruitment challenges and insights into intervention delivery within football club contexts.

Understanding Sex- and Age-Specific Suicide Risk Indicators: Insights from a Large Swedish Case-Control Study
newsage differencesepidemiology

Understanding Sex- and Age-Specific Suicide Risk Indicators: Insights from a Large Swedish Case-Control Study

By MedXY|Oct 31, 2025

This Swedish population-based study highlights how suicide risk indicators vary by sex and age, showing males and older adults exhibit fewer, but often higher absolute risk indicators, underscoring the need for tailored suicide prevention s

Systemic Inflammation as a Modulator of Anhedonia in Major Depressive Disorder: Insights from an LPS Challenge Trial
newsAnhedoniamajor depressive disorder

Systemic Inflammation as a Modulator of Anhedonia in Major Depressive Disorder: Insights from an LPS Challenge Trial

By MedXY|Oct 31, 2025

This RCT reveals that adults with major depressive disorder and elevated systemic inflammation exhibit heightened anhedonic responses to an inflammatory challenge, highlighting inflammation’s role in depression symptomatology.

Unraveling Genetic Links Between Problematic Alcohol Use and Psychiatric Disorders: Insights from Large-Scale Genomic Analyses
Internal MedicineGWASpsychiatric disorders

Unraveling Genetic Links Between Problematic Alcohol Use and Psychiatric Disorders: Insights from Large-Scale Genomic Analyses

By MedXY|Oct 30, 2025

This study reveals significant shared genetic architectures between problematic alcohol use and various psychiatric disorders, identifying key genes like TTC12 and ANKK1 that may underlie their comorbidity.

Cognitive Control Deficits in Specific Problematic Internet Uses: Insights From Clinically Validated Neurocognitive Assessments
Neurologycognitive impairmentExecutive Function

Cognitive Control Deficits in Specific Problematic Internet Uses: Insights From Clinically Validated Neurocognitive Assessments

By MedXY|Oct 30, 2025

This study reveals distinct impairments in executive functions and inhibitory control across types of problematic internet use, highlighting the need for tailored interventions to address self-control deficits in internet addiction.

Polygenic Influences and Anticholinergic Burden: Unraveling Their Joint Impact on Cognition and Brain Structure in Psychosis Spectrum Disorders
Neurologybrain structurecognition

Polygenic Influences and Anticholinergic Burden: Unraveling Their Joint Impact on Cognition and Brain Structure in Psychosis Spectrum Disorders

By MedXY|Oct 30, 2025

This study reveals that genetic predispositions interact with anticholinergic medication burden to influence cognitive deficits and brain gray matter volume reductions in psychosis spectrum disorders, offering new insights into personalized

Cognition-Guided EEG Neurofeedback Enhances Response Inhibition in Methamphetamine Use Disorder: A Promising Neuromodulation Approach
NeurologyEEGMethamphetamine Use Disorder

Cognition-Guided EEG Neurofeedback Enhances Response Inhibition in Methamphetamine Use Disorder: A Promising Neuromodulation Approach

By MedXY|Oct 30, 2025

Cognition-guided EEG neurofeedback targeting methamphetamine cue-related brain activity significantly improves response inhibition in men with methamphetamine use disorder, surpassing standard rehabilitation outcomes and offering a novel in

Telehealth Prescribing of ADHD Stimulants: Assessing Risks for Subsequent Substance Use Disorders
newsADHDStimulant Use Disorder

Telehealth Prescribing of ADHD Stimulants: Assessing Risks for Subsequent Substance Use Disorders

By MedXY|Oct 30, 2025

This study evaluates whether initiating ADHD stimulant prescriptions via telehealth affects later risks of stimulant or other substance use disorders, finding no SUD risk increase but a potential rise in stimulant use disorder risk.

Prev
12 / 20
1…1011121314…20
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Browse by specialty

Open language-specific specialty feeds and department pages.

news6829 articlesCardiology1403 articlesClinical Updates1315 articlesOncology1176 articlesDiabetes & Endocrinology868 articlesNeurology834 articlesPublic Health605 articlesGastroenterology586 articles
Hematology-Oncology
513 articles
Pediatrics493 articles
Internal Medicine464 articles